Logo image of ZSAN

Zosano Pharma Corporation (ZSAN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ZSAN - US98979H3012 - Common Stock

0.5576
+0.04 (+7.23%)
Last: 6/10/2022, 8:00:56 PM
0.5459
-0.01 (-2.1%)
After Hours: 6/10/2022, 8:00:56 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ZSAN. ZSAN was compared to 187 industry peers in the Health Care Equipment & Supplies industry. The financial health of ZSAN is average, but there are quite some concerns on its profitability. ZSAN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ZSAN had negative earnings in the past year.
ZSAN Yearly Net Income VS EBIT VS OCF VS FCFZSAN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 -10M -20M -30M -40M

1.2 Ratios

Industry RankSector Rank
ROA -208.66%
ROE 41.36%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ZSAN Yearly ROA, ROE, ROICZSAN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 -200 -400 -600

1.3 Margins

Industry RankSector Rank
OM -4681.82%
PM (TTM) -8362.12%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZSAN Yearly Profit, Operating, Gross MarginsZSAN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 -5K -10K -15K

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, ZSAN has less shares outstanding
Compared to 1 year ago, ZSAN has an improved debt to assets ratio.
ZSAN Yearly Shares OutstandingZSAN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M
ZSAN Yearly Total Debt VS Total AssetsZSAN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M

2.2 Solvency

ZSAN has an Altman-Z score of -27.38. This is a bad value and indicates that ZSAN is not financially healthy and even has some risk of bankruptcy.
ZSAN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -27.38
ROIC/WACCN/A
WACCN/A
ZSAN Yearly LT Debt VS Equity VS FCFZSAN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 20M -20M 40M -40M

2.3 Liquidity

ZSAN has a Current Ratio of 1.61. This is a normal value and indicates that ZSAN is financially healthy and should not expect problems in meeting its short term obligations.
ZSAN has a Quick Ratio of 1.61. This is a normal value and indicates that ZSAN is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 1.61
Quick Ratio 1.61
ZSAN Yearly Current Assets VS Current LiabilitesZSAN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M

More info and screens

2

3. Growth

3.1 Past

The earnings per share for ZSAN have decreased strongly by -1951.22% in the last year.
Looking at the last year, ZSAN shows a very strong growth in Revenue. The Revenue has grown by 37.50%.
ZSAN shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -6.63% yearly.
EPS 1Y (TTM)-1951.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2100%
Revenue 1Y (TTM)37.5%
Revenue growth 3YN/A
Revenue growth 5Y-6.63%
Sales Q2Q%-50%

3.2 Future

The Earnings Per Share is expected to grow by 18.47% on average over the next years. This is quite good.
ZSAN is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -18.92% yearly.
EPS Next Y98.64%
EPS Next 2Y40.94%
EPS Next 3Y25.57%
EPS Next 5Y18.47%
Revenue Next Year-90.9%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-18.92%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ZSAN Yearly Revenue VS EstimatesZSAN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2020 2021 2022 500K 1M 1.5M 2M 2.5M
ZSAN Yearly EPS VS EstimatesZSAN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -500 -1K -1.5K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ZSAN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ZSAN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZSAN Price Earnings VS Forward Price EarningsZSAN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.31
ZSAN Per share dataZSAN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6 -8

4.3 Compensation for Growth

A more expensive valuation may be justified as ZSAN's earnings are expected to grow with 25.57% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.94%
EPS Next 3Y25.57%

More info and screens

0

5. Dividend

5.1 Amount

ZSAN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Zosano Pharma Corporation

NASDAQ:ZSAN (6/10/2022, 8:00:56 PM)

After market: 0.5459 -0.01 (-2.1%)

0.5576

+0.04 (+7.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-13 2022-05-13/amc
Earnings (Next)08-08 2022-08-08
Inst Owners2.49%
Inst Owner Change0%
Ins Owners323.29%
Ins Owner Change0%
Market Cap2.73M
Revenue(TTM)660.00K
Net Income(TTM)-55.19M
Analysts45.71
Price Target21.42 (3741.46%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.14
P/FCF N/A
P/OCF N/A
P/B 0.19
P/tB N/A
EV/EBITDA 0.31
EPS(TTM)-8.41
EYN/A
EPS(NY)-0.09
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.13
BVpS2.87
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -208.66%
ROE 41.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -4681.82%
PM (TTM) -8362.12%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y1%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.61
Quick Ratio 1.61
Altman-Z -27.38
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1951.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2100%
EPS Next Y98.64%
EPS Next 2Y40.94%
EPS Next 3Y25.57%
EPS Next 5Y18.47%
Revenue 1Y (TTM)37.5%
Revenue growth 3YN/A
Revenue growth 5Y-6.63%
Sales Q2Q%-50%
Revenue Next Year-90.9%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-18.92%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

Zosano Pharma Corporation / ZSAN FAQ

Can you provide the ChartMill fundamental rating for Zosano Pharma Corporation?

ChartMill assigns a fundamental rating of 3 / 10 to ZSAN.


Can you provide the valuation status for Zosano Pharma Corporation?

ChartMill assigns a valuation rating of 3 / 10 to Zosano Pharma Corporation (ZSAN). This can be considered as Overvalued.


How profitable is Zosano Pharma Corporation (ZSAN) stock?

Zosano Pharma Corporation (ZSAN) has a profitability rating of 3 / 10.


How financially healthy is Zosano Pharma Corporation?

The financial health rating of Zosano Pharma Corporation (ZSAN) is 2 / 10.


What is the expected EPS growth for Zosano Pharma Corporation (ZSAN) stock?

The Earnings per Share (EPS) of Zosano Pharma Corporation (ZSAN) is expected to grow by 98.64% in the next year.